Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | DHODH | Q02127 | 5/20 | 0.69 |
| ▸ | TACR3 | P29371 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TACR2 | P21452 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373101 | 0.87 | MAPT (0.69) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL4879045 | 0.87 | DHODH (0.71) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL4875991 | 0.86 | KDM4E (0.55) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL5945348 | 0.86 | DHODH (0.63) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL4230222 | 0.85 | DHODH (0.70) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL2459661 | 0.85 | DHODH (0.72) | DHODHCYP3A4 | |
| Hydrochloric Acid SCHEMBL6848801 | 0.85 | DHODH (0.61) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL5945357 | 0.85 | PDE10A (0.68) | PDE10ATSHRDHODHTACR3SMN1; SMN2 | |
| SCHEMBL1581468 | 0.84 | PDE10A (1.00) | PDE10ATSHRDHODHKMT2ACYP2C19 | |
| SCHEMBL2373011 | 0.84 | DHODH (0.58) | PDE10ATSHRDHODHTACR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
| EP-1131294-B1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | GLAXOSMITHKLINE SPA (IT) | 2006-12-20 | — | — | EP | disclosed |
| EP-1334088-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002044154-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002038548-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038547-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-05-16 | — | — | WO | disclosed |
| EP-1131294-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031038-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | TACR3, GRIK3, TACR2 | PDE10A 2035/4885TSHR 971/4885DHODH 3942/4885 |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | PDE10A 1523/4885TSHR 340/4885DHODH 2897/4885 |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | PDE10A 2268/4885TSHR 2692/4885DHODH 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.